Skip to content

Turkish Version of Pelvi-Perineal Surgery Sexuality Questionnaire

Turkish Version of Pelvi-Perineal Surgery Sexuality Questionnaire: Translation, Cultural Adaptation and Validation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07090213
Enrollment
113
Registered
2025-07-29
Start date
2025-07-22
Completion date
2026-01-05
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery; Maternal, Uterus or Pelvic Organs, Affecting Fetus

Keywords

validation, cultural adaptation, pelvic surgery

Brief summary

This prospective, multicentre observational study translates the 13-item Pelvi-Perineal Surgery Sexuality Questionnaire (PPSSQ) from French to Turkish, culturally adapts it, and evaluates its reliability, validity and responsiveness in Turkish-speaking women covering from pelvic floor surgery.

Detailed description

Sexual function is a key outcome after incontinence or prolapse surgery; however, no Turkish tool specifically captures surgery-related sexual issues. The Pelvi-Perineal Surgery Sexuality Questionnaire (PPSSQ) was recently validated in France and measures two dimensions (Sexual Health and Discomfort & Pain) with good psychometric performance. The English version of PPSSQ will be adapted for Turkish use according to the established guidelines for cross-cultural adaptation of self-reported questionnaires. The guideline has 5 steps: (1) translation, (2) synthesis, (3) back translation, (4) evaluation by a team of experts, and (5) pretests. 80 sexually active and inactive women (≥18 y) with mid-urethral sling, vaginal or laparoscopic prolapse repair (with/without mesh) will be recruited. Participants will complete the Turkish version of the Female Sexual Function Index (FSFI-Turkish) on the first visit and again 7 days later for validation purposes. Internal consistency will be tested using Cronbach's alpha, and the test-retest reliability will be assessed by calculating the intra-class correlation coefficient.

Interventions

Eighty women, determined by the number of questions times the rule of 10, will be asked to fill out the Pelvi-Perineal Surgery Sexuality Questionnaire - PPSSQ and Female Sexual Function Index (FSFI) questionnaires and will be asked to fill out the PPSSQ again 7 days later for test-retest reliability.

Sponsors

Bezmialem Vakif University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Having had pelvic surgery more than 12 months ago * Being sexually active for the last three months * Being literate

Exclusion criteria

* Not having had a sexual partner for at least three months * Receiving anti-estrogen therapy for any reason * Having a history of gynecological or breast cancer * Not understanding written Turkish

Design outcomes

Primary

MeasureTime frameDescription
Pelvi-Perineal Surgery Sexuality Questionnaire1 weekThe Pelvi-Perineal Surgery Sexuality Questionnaire (PPSSQ) is a 13-question self-questionnaire validated in a population of sexually active women or not, operated on for stress urinary incontinence or pelvic organ prolapse by laparoscopy or vaginal surgery, with or without mesh. The domains are Sexual Health and Discomfort and Pain. The questionnaire is calculated out of 100 points, with a higher score indicating better sexual function.

Secondary

MeasureTime frameDescription
Female Sexual Function Index (FSFI)1 weekIt is a 19-item multidimensional self-reporting measure that quantified female sexual dysfunction in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. These questions ask about patients' sexual feelings and responses during the past 4 weeks. FSFI use a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual functioning.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026